Primary Hyperparathyroidism
Conditions
Brief summary
Despite the strong association of hyperparathyroidism with arachidonic acid related lipid signals, little research has been performed over the years. A better understanding of the link between arachidonic acid remodeling, prostaglandin and endocannabinoid production with primary hyperparathyroidism in primary tissue/cells might open up new avenues for biomarker and thus to a potential therapeutic target. Arachidonic acid remodeling might also have an impact on depression and elevated cytokines in patients with primary hyperparathyroidism. The investigators therefore will assess the correlation between postoperative improvement of PHQ-9 and cytokine levels with arachidonic acid remodeling.
Interventions
None listed
Sponsors
Insel Gruppe AG, University Hospital Bern
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Primary hyperparathyroidism with planned surgery * Written informed consent
Exclusion criteria
* Age \<18 years * Secondary/tertiary hyperparathyroidism * Renal insufficiency * Participant is pregnant * Participant is incapable of giving an informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Activity-based protein profiling (ABPP) will be used to assess the enzymes involved in calcium induced stress signals and endocannabinoid activation | 2 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of the level of calcium | 2 months | — |
| Measurement of the level of cortisol | 2 months | — |
| Measurement of the level of 25-hydroxyvitamin D | 2 months | — |
| Measurement of the level of parathyroid hormone | 2 months | — |
| Measurement of the level of endocannabinoids, arachidonic acid species, prostanoids and related anti-inflammatory lipids | 2 months | — |
| Measurement of the level of IL-6 and TNF-α | 2 months | — |
| Assessment of Patient Health Questionnaire - 9 | 2 months | The Patient Health Questionnaire (PHQ-9) is described as a valid depression scale with good sensitivity and specificity for detecting depressive disorders, ranging from 1 to 27. Depression severity: 1 to 4: minimal; 5 to 9: mild; 10 to 14: moderate; 15 to 19: moderately severe; 20 to 27: severe |
| Measurement of the levels of the enzymes involved in the endocannabinoid system activation (diacylglycerol lipase; monoacylglycerol lipase, phospholipases, cyclooxygenases) | 2 months | — |
Countries
Switzerland
Outcome results
None listed